The CCCA submitted a general comment to the Canada Gazette website and to Mr. Bruno Rodrigue, Executive Director, Office of Legislative and Regulatory Modernization, regarding proposed amendments to the Food and Drugs Act concerning Agile Regulations. These regulations will change the licensing process for novel therapeutics in Canada. The requirements for a product’s approval will be lessened from current standards and this may impact the safety of the product’s being used by Canadians. After approval, post-marketing assessments will be used, but this is not an effective way to prove harms were caused by a product. These regulations will also be used for veterinary products, meaning they may end up in the food supply.